Finding. In cobalt-chloride hypoxia, baicalein plus thermal-cycling stimulation kills A549 lung-cancer cells and largely leaves IMR-90 fibroblasts alone. The combination lowers HIF-1α and mitochondrial SOD2, raises reactive oxygen species, cuts the DNA-sanitizing enzyme MTH1, collapses mitochondrial membrane potential, and cleaves PARP. Hypoxic NSCLC cells that were using HIF and a mitochondrial antioxidant to stay alive lose both.
Why this paper matters
Tumor hypoxia stabilizes HIF-1α and is a standard excuse for therapy resistance. This paper’s bet is that a flavonoid plus a physical cycling heat/cool stimulus can strip that shield without a blunt cytotoxic on normal lung fibroblasts. The mitochondrial clause is SOD2 and membrane potential: they are not treating respiration as a side assay. They are treating the organelle’s antioxidant and potential as part of the kill.
It is still a dish paper. A549 plus CoCl2 is a workhorse, not a tumor. File it as a hypoxic ROS/HIF combination note with a mitochondrial-potential readout.
What they actually measured
Viability and apoptosis in A549 versus IMR-90 under CoCl2. Mechanistic panel: HIF-1α and SOD2 protein down, intracellular ROS up, MTH1 down, mitochondrial membrane potential disrupted, PARP cleavage up. That is a coherent apoptosis-plus-oxidative-stress stack.
What is missing is as important as what is present. There is no oxygen-consumption trace, no electron-transport subunit list, and no animal. TCS is described as sparing normal cells, but the parameters live in the PDF. CoCl2 is a HIF mimetic; it is not a hypoxic chamber.
How to read the score
Low-to-mid seventies for a mitochondrial desk. SOD2 and ΔΨ are real organelle hooks, but this is one cell line, chemical hypoxia, and a combination whose clinical path is undefined. Confidence is medium-low on translation and medium on the in-vitro descriptive claim. We score it 74: keep it in the corpus because of the mitochondrial antioxidant/potential axis, not because NSCLC therapy just changed.
What to do with it
Track if you collect HIF–SOD2–ROS papers or thermal-biology plus flavonoid combinations. Pull the ΔΨ and SOD2 blots. Do not add baicalein or TCS to a treatment list. The directional implication is that hypoxic A549 survival in this setup depends on a HIF-1α/SOD2 buffer that the combination removes.